CN1348003A - Hirudin gene hv 2-47k and its synthesis and expression - Google Patents

Hirudin gene hv 2-47k and its synthesis and expression Download PDF

Info

Publication number
CN1348003A
CN1348003A CN 00129747 CN00129747A CN1348003A CN 1348003 A CN1348003 A CN 1348003A CN 00129747 CN00129747 CN 00129747 CN 00129747 A CN00129747 A CN 00129747A CN 1348003 A CN1348003 A CN 1348003A
Authority
CN
China
Prior art keywords
hirudin
gene
novel
asn
pcr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN 00129747
Other languages
Chinese (zh)
Inventor
黄秀东
游自立
吕志强
肖建国
于廷和
王立兵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tang Dejiang
Original Assignee
梅伯皋
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 梅伯皋 filed Critical 梅伯皋
Priority to CN 00129747 priority Critical patent/CN1348003A/en
Publication of CN1348003A publication Critical patent/CN1348003A/en
Pending legal-status Critical Current

Links

Images

Landscapes

  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Based on the amino acid sequence data of over twenty natural hirudin mutants and by using HV2 hirudin as prototype, novel hurudin gene hv2-47k capable of inserting pPIC9 vector is finally obtained through replacing the asparagine (N) with lysine (K), selecting methanol yeast Picha pastoris preferred genetic codon, synthesizing eight-section deoxynucleotide segment (primer) and recursive PCR splice. The gene hv2-47k is expressed in secretion mode in methanol yeast Pichia pastoris, and in cylinder fermentation, the novel hirudin expression amount in the fermented supernatant liquid is not lower than 30000 ATU/ml (after inducement for 50 hr) or 2.0 g/L yield.

Description

Hirudin gene hv2-47k and synthetic and expression thereof
The present invention relates to a kind of reconstituted drug, particularly hirudin gene and synthetic and expression thereof.
R-hirudin (Hirudin) is to separate a class polypeptide that obtains from Hirudo japonica (Hirudomedicinalis) sialisterium the earliest.Afterwards, the investigator separates the r-hirudin varient that obtains as many as 20 kinds from various bloodthirsty leech, they mostly are made up of more than 60 (64-69 is not waited) amino-acid residues, wherein maximum three kinds of varients (HirudinVariants) of being made up of 65 or 66 amino acid are used in research, be called HV1, HV2 and HV3, all natural hirudin C-hold all sulphatings (RobertHand, et al Transgenica-Topics in Clinical Biotechnology http://pharminfo.com/pubs/transgen/th-hir.html) of the 63rd tyrosine Tyr (Y).
R-hirudin all has very high avidity to people and other mammiferous zymoplasms, is the strongest zymoplasm natural inhibitor of finding so far.It is in conjunction with the center irreversible combination to take place by catalytic center and Fibrinogen with zymoplasm, makes the zymoplasm inactivation.R-hirudin of a part and the zymoplasm of a part form firm, non-covalent mixture, and therefore, the zymoplasm of inactivation is irreversible basically, and this just makes the hematoblastic activation process of fibrinogenic conversion and thrombin-mediated be blocked.
The N-end (1~39) of r-hirudin mainly contains hydrophobic amino acid, stablize by three intrachain disulfide bonds, and C-end (40~65) is rich in tart amino acid, and wherein the peptide section of 10 amino-acid residues compositions of C-end is specificity bind thrombin and the critical area that makes it inactivation.47 Methionins (K) residue to HV1 and HV3 discovers that K is to the active of r-hirudin and with the interaction of zymoplasm also very important (Mao, S.J.T., etal., Anal.Biochem.161:514-518,1987; Harvey, R.P., etal., PNAS (USA) 83:1084-1088,1986; Dodt, J., etal., FEBSLett.2 29:87-90,1988).The three-dimensional structure that 47 Methionins of HV2 may influence r-hirudin simultaneously by hydrogen bond and electrostatic interaction with and with the combination of zymoplasm, its thermostability is increased, biological activity improves 61% (Chinese biological chemistry and molecular biology journal such as Lu Yu peak, 1998; 14 (1): 32-37)
Limited in view of the natural hirudin source, in the later stage eighties, all begin one's study both at home and abroad and adopt genetic engineering technique to produce lepirudin 023 ludon, to satisfy the needs of pharmacology and clinical study test.The company that is engaged at present hirudin gene engineering research exploitation abroad is as many as 11 families.Wherein German Hoechst company holds primary Isoleucine (I) to become leucine (L) N of HV2, the 2 63 the tyrosine Tyr desulfurization r-hirudin Lepirudin (chemical name of producing: Leu1, Thr2-63-desulfohirudin, trade(brand)name REFLUDAN), its powder injection successively went on the market in the Europe and the U.S. in 1998, be used for the treatment of the thrombocytopenia (HIT, Heparin-induced thrombocytopenia) that heparin brings out.The 63rd the desulfurization r-hirudin that the Ciba-Geigy of Switzerland (NOVARTIS) company adopts recombinant technology to express in cereuisiae fermentum, called after Desirudin, trade(brand)name Revasc, be mainly used in the complication after bone surgery and other major operations, as dvt (DVT, Deep vein thrombo-sis) and pulmonary infarction (PE, Pulmonary embo lism), existing in Europe listing (Aventis-Refludan Prescribing Information http://www.Aventispharma-s.com/Pis/refludan-TXT.html).
Through after the analysis-by-synthesis, I am based on the aminoacid sequence of HV2, simultaneously with reference to HV1, the sequence of HV3,47 the l-asparagine (N) of HV2 is substituted by Methionin (K), the genetic codon of selecting for use methanol yeast Pichia pastoris to be liked, 8 sections oligonucleotide chains of synthetic (primer) (chain length 31-46 base does not wait), adopt recursion PCR (Recursive PCR) (Bi Qun, Huang Yixiu, the recurrence PCR of Zhu's hirudin gene in holy heptan synthetic and expression in intestinal bacteria and secretion Peking University's journal (natural science edition) 33 (6): 737-742,1997), splice novel this gene of r-hirudin hv2-47K and it is inserted among the Pichia yeast secretion type expression carrier pPIC9 construction of expression vector PIC8.2.Transform the Pichia yeast with this carrier, obtain the engineering bacteria that efficiently expresses.To the effect that of the present invention: 1.hv2-47k gene synthetic
According to the HV2-47K aminoacid sequence of design, consider the expression vector that will use, determine after the analysis of machine Autocad that as calculated full length gene is 222bp.We synthesize 8 oligonucleotide fragment/primers altogether to obtain this gene.For guaranteeing that the HV2 gene produces minimum assorted band through recursion PCR, every primer is with about 15 base pairs of adjacent primer strand complementary cohesive end.Because the carrier of selecting Pichia yeast secretion type expression carrier pPIC9 to insert as gene, so 5 '-ends in HV2-47K structure gene are designed the XhoI restriction enzyme site, and hold the codon that inserts KEX2 protease recognition sequence (K-R) between first amino-acid residue at this site and HV2-47K N-, so that target protein can successfully cut signal peptide when secretion; 3 '-end is TAA terminator codon and EcoRI restriction enzyme site (Fig. 1).Like this after the gene splicing success, through XhoI with EcoRI is two cuts, just can be inserted into the pPIC9 expression vector, construction of expression vector PIC8.2 (Fig. 3).2.hv2-47k Gene Sequence Analysis
The pPIC9 plasmid vector is a kind of shuttle vectors of Invitrogen company design, its plasmid that can increase in bacterium, the goal gene of integrating in yeast, inserting.This carrier has three sequencing primers: two target gene 5s '-the end primer (5 '-AOX1,2-Factor Seq) and one 3 '-the end primer (3 '-AOX1).Therefore; the structure of screening, order-checking and expression vector once can be finished; because the hv2-47k goal gene has only 222bp long; be inserted between the multiple clone site XhoI-EcoRI of pPIC9; so we select 5 for use '-the AOX1 primer is to goal gene in the pPIC9 expression plasmid check order (measure in last sea base health (Genecore) company, sequencer address is seen Fig. 2).By the result of order-checking as seen, the base sequence of goal gene does not go wrong when recurrence PCR splice, its 5 '-the XhoI point of contact of end, the base sequence of KEX2 enzyme recognition sequence (K-R), 3 '-end TAA termination codon and EcoRI restriction enzyme site be all with original design identical.In addition, from 3 '-end EcoRI site extend back AVrII, NotI restriction enzyme site the multiple clone site (MCS) of visible pPIC9.3.hv2-47k expression of gene
Express novel r-hirudin HV2-47K with the GS115-HV2-47K Pichia Yeast engineering bacteria that methanol induction makes up, adopt antithrombin vigor assay excretory r-hirudin amount (being the ATU of anti-freezing unit) to determine its expression level.Because the hv2-47k gene is a genetic codon of selecting for use methanol yeast Pichia pastoris to be liked, when shake-flask culture, hv2-47k gene expression amount in Pichia zymic nutrient solution supernatant is not less than 2,000ATU/ml (inducing 50 hours); When the 30L fermentation cylinder for fermentation, expression amount is not less than 30, and 000ATU/ml (inducing 50 hours) is equivalent to the output of 2.0g/L.
Synthetic eight sections few nucleic acid (primer) of embodiment 1:hv2-47k gene all synthesize in Shanghai bio-engineering corporation (Sangon), reclaim through the PAGE electrophoresis, are packed as the 10D/ pipe, synthetic numbering: 33502~33509, number certainly: P1~P8, in September, 97).The synoptic diagram of eight sections primer splicings is as follows:
Figure A0012974700091
For avoiding the phase mutual interference between the primer, earlier P3, P4, P5 and P6 are mixed and carry out first round PCR reaction, obtain one section of the centre of hv2-47k gene, be primer with P2, P7 again, first round PCR product is that template is carried out second and taken turns PCR, obtain the part broad in the middle of hv2-47k gene, taking turns the PCR product with second at last is template, is that primer splices complete hv2-47k gene with P1, P8.
3 PCR reactions of whole splicing experience can be finished, and PCR process and condition are as follows: PCR reaction (PCR-1) for the first time: 20ul reaction system: 0.3ul ... P40.3ul ... P52ul ... P32ul ... P61ul ... Mix-d NTP (every kind of dNTP contains 5mM) 2ul ... 10xTaq-plus damping fluid 1ul ... it is 20ul to cumulative volume that Taq-plus enzyme (cushioning, be diluted to 1u/ul with lxTaq-plus) adds ultrapure water 11.4ul.PCR reaction (PCR-2) for the second time: 20ul reaction system: 4ul ... PCR-1 reaction product 2ul ... P22ul ... P71ul ... Mix-d NTP (every kind of dNTP contains 5mM) 2ul ... 10xTaq-plus damping fluid 1ul ... Taq-plus enzyme (cushioning, be diluted to 1u/ul) with lxTaq-plus
Adding ultrapure water 8.0ul is 20ul to cumulative volume.PCR reaction (PCR-3) for the third time: 100ul reaction system: 5ul ... PCR-2 reaction product 4ul ... P14ul ... P83ul ... Mixed-dNTP (every kind of dNTP contains 5mM) 10ul ... Taq-plus damping fluid 1ul ... Taq-plus enzyme (proenzyme dress liquid, the suitable 5u of 1ul)
Adding ultrapure water 73ul is 100ul to cumulative volume.The reaction parameter setting of PCR: PCR-1, PCR-2 all take turns at 94 ℃, 60S/58 ℃, 70S/72 ℃, 70S circulation 30, finish rear electrophoresis at every turn and inspect, and determine that specificity is good, and when having only a band, just negate answers product to make the template of next round PCR.Since our design draw the complimentary piece segment length, whenever do not produce assorted band when taking turns PCR, thereby last round of PCR product can use as template directly.PCR-3 takes turns at 94 ℃, 60S/58 ℃, 70S/72 ℃, 70S circulation 30, and 72 ℃ were extended 6 minutes.Each step PCR product of whole recurrence PCR in 1.2% agarose gel electrophoresis result as shown in Figure 4.The structure of embodiment 2:hv2-47k expression vector PIC8.2 adopts the post absorption method to collect the target gene fragment that amplifies the PCR-3 product, cuts with XhoI-EcoRI is two, and glue reclaims and connects usefulness; Get the pPIC9 plasmid, cut with XhoI-EcoRI is two equally, glue reclaims big fragment and connects and use carrier.Set up following ligation system: 7ul ... hv2-47k gene 1ul after the recovery ... pPIC9 carrier 1ul after the recovery ... 10XT4 dna ligase 0.5ul ... T4 dna ligase (about 3U) 0.5ul ... dH2010ul ... total reaction volume is the condition of ligation: 22 ℃, 60 minutes, 65 ℃, 10 minutes.Ligation liquid is transformed E coli TOP10F ' competent cell born of the same parents with the Calcium Chloride Method preparation, and method is referring to J.Sambrook etal, Molecular Cloning a laboratory Mannual, and 2nded 1989.Bacterium after the conversion is layered on the LB+Amp plate, choosing positive colony from the LB+Amp flat board cultivates, extract plasmid, with XhoI, the screening of EcoRI double digestion method, the energy enzyme cuts out about 220 (216) bp band persons and is the PIC9 plasmid that is inserted in the hv2-47k gene, with 5 '-(Invitrogen Kit provides the AOX1 primer, or the sequence that provides by Kit is synthetic) to objective gene sequencing, the result shows: recurrence PCR splices the sequence requirement that the hv2-47k gene conforms with design fully, and is special with expression plasmid called after PIC8.2.Structure gene nucleotide sequence such as Fig. 2 of hv2-47k, building process as shown in Figure 3.Embodiment 3: the GS115-HV2-47K Pichia Yeast engineering bacteria 1 of structure). and Ecoli Top10F ' bacterium that preparation conversion Pichia zymic expression vector PIC8.2 plasmid will contain the PIC8.2 plasmid is in the LB+Amp+Kan liquid culture, with alkali extraction process large quantity extracting plasmid.The PIC8.2 plasmid linearization is made to transform the usefulness of Pichia yeast host bacterium GS115 with SalI.2) the .Pichia zymic transforms with linearizing PIC8.2 expression vector dna transformed competence colibacillus Pichia yeast GS115His --Mut +Host bacterium (competence adopts the Pichia Easy CompTransformation Kit preparation of Invitrogen company), press Pichia Expression Kit-ProteinExpression, Catalog No:K1710-01) described in step transform and screen.Because of host GS115 is His -(histidine defect type), can not the MD plate on growth (1.34%YNB, 4 * 10 -5%Biotin, 2%Dextrose 1.5%Agar), has only the successful transformant of conversion to grow.3) screening of .GS115-HV2-47K Pichia Yeast engineering bacteria is chosen single bacterium colony from the MD plate, be inoculated into and contain 10mlYPD substratum (1%Yeast extract, 2%Peptone, 2%Dextose), cultivated 30 hours for 30 ℃, under the condition of aseptic technique, it is that 50ml shakes in the bottle that the collection thalline forwards the volume that contains 10mlMM inducing culture liquid to, be not less than 300 rev/mins of cultivations down, and, getting a sample and detect hirudin activity every 10 hours.Adding anhydrous methanol after each sampling is 0.5-1.0% to final concentration.The about 60-70 of inducing culture hour.High expression level amount (when hirudin activity is the highest) occurred between 55-65 hour.Constant relatively for guaranteeing the nutrient solution volume, take out how many samples at every turn, just add the MM nutrient solution of respective volume, other adds about 0.5ml distilled water and replenishes the water that evaporates.Finally obtain the Pichia Yeast engineering bacteria that to express HV2-47K, called after GS115-HV2-47KPichia yeast.Curve is as shown in Figure 5 over time for the expression amount of HV2-47K.
The r-hirudin hv2-47k gene base sequence and the aminoacid sequence of description of drawings: Fig. 1 design
5 '-hold to be restriction enzyme XhoI recognition sequence CTCGAG, and KEX2 protease recognition sequence amino acid correspondence
Codon AAAAGA; 3 '-hold sequencing result into terminator codon TAA and limiting enzyme EcoRI recognition sequence GAATTC Fig. 2 recurrence PCR method splicing hv2-47k
This figure has only intercepted the key component of former sequencer address, and wherein the fragment between XhoI point of contact and the EcoRI point of contact promptly
It is the agarose gel electrophoresis of three step of the process synoptic diagram Fig. 4 recurrence PCR method pcr amplification product of hv2-47k gene fragment Fig. 3 construction of expression vector PIC8.2
PCR-1: first round PCR product
PCR-2: second takes turns the PCR product
PCR-3: third round PCR product promptly obtains final hv2-47k gene
100bp Ladder +Be dna molecular amount standard map 5 r-hirudin HV2-47k expression amount curve over time in Pichia pastoris
Wen Zhongyong capitalization roman HV2-47k represents the r-hirudin albumen that engineering bacteria is expressed, and represents hirudin gene with small letter italic hv2-47k.

Claims (4)

1. the novel r-hirudin HV2-47K of genetically engineered drug is characterized by, and this medicine is a genetic code of selecting for use methanol yeast Pichia pastoris to be liked, and the gene hv2-47k of synthetic expresses in the Pichia yeast and gets;
2. novel hirudin gene hv2-47k according to claim 1 and amino acid sequence coded thereof are as follows: CTC GAG AAA AGA ATT ACT TAC ACT GAT TGT ACA GAA TCG
Ile Thr Tyr Thr Asp Cys Thr Glu SerGGT CAA AAT TTG TGC CTC TGC GAG GGA AGC AAT GTT TGCGly Gln Asn Leu Cys Leu Cys Glu Gly Ser Asn Val CysGGT AAA GGC AAT AAG TGC ATA TTG GGT TCT AAT GGA AAGGly Lys Gly Asn Lys Cys Ile Leu Gly Ser Asn Gly LysGGC AAC CAA TGT GTC ACT GGC GAA GGT ACA CCG AAG CCTGly Asn Gln Cys Val Thr Gly Glu Gly Thr Pro Lys ProGAA AGC CAT AAC AAC GGC GAT TTC GAA GAA ATT CCA GAAGlu Ser His Asn Asn Gly Asp Phe Glu Glu Ile Pro GluGAA TAT TTA CAA TAA GAA TTCGlu Tyr Leu Gln
3. novel hirudin gene hv2-47k according to claim 1 can insert different expression vectors, selects eucaryon or procaryotic cell expression host to express, and does not insert the pPIC9 carrier and be not only limited to, and is transformed into and expresses in the Pichia yeast;
4. novel hirudin gene sequence according to claim 2 and aminoacid sequence thereof, the genetic code of every seed amino acid can be selected the different degenerate codons of the primary structure that does not influence novel r-hirudin HV2-47K for use, and is not limited only to the codon that the Pichia yeast is liked.
CN 00129747 2000-10-10 2000-10-10 Hirudin gene hv 2-47k and its synthesis and expression Pending CN1348003A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 00129747 CN1348003A (en) 2000-10-10 2000-10-10 Hirudin gene hv 2-47k and its synthesis and expression

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 00129747 CN1348003A (en) 2000-10-10 2000-10-10 Hirudin gene hv 2-47k and its synthesis and expression

Publications (1)

Publication Number Publication Date
CN1348003A true CN1348003A (en) 2002-05-08

Family

ID=4593708

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 00129747 Pending CN1348003A (en) 2000-10-10 2000-10-10 Hirudin gene hv 2-47k and its synthesis and expression

Country Status (1)

Country Link
CN (1) CN1348003A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1328380C (en) * 2001-09-24 2007-07-25 天津天士力制药股份有限公司 High-efficiency expression recombinant hirudin and producing method thereof
CN102191264A (en) * 2011-04-02 2011-09-21 江苏省中医药研究院 Production method of recombined hirudin

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1328380C (en) * 2001-09-24 2007-07-25 天津天士力制药股份有限公司 High-efficiency expression recombinant hirudin and producing method thereof
CN102191264A (en) * 2011-04-02 2011-09-21 江苏省中医药研究院 Production method of recombined hirudin

Similar Documents

Publication Publication Date Title
CA1240940A (en) A-factor and its processing signals
EP0637630A2 (en) Method for the biological synthesis of peptides
EP0020147B2 (en) A dna transfer vector for human pre-growth hormone, a microorganism transformed thereby, and a method of cloning therefor
CN113444167A (en) Recombinant human collagen polypeptide and application thereof
AU590238B2 (en) Recombinant methods for production of serine protease inhibitors and dna sequences useful for same
CN1138856C (en) Epidermal growth factor engineering bacteria and method for preparing epidermal growth factor using the bacteria
CN110724187B (en) Recombinant engineering bacterium for efficiently expressing liraglutide precursor and application thereof
KR101026526B1 (en) How E. coli secrete foreign proteins
CN108840951A (en) A kind of fusion protein and preparation method thereof being made of pig albumin, Porcine interferon-gamma and porcine interferon alpha
ATE542913T1 (en) PROMOTOR VARIANTS FOR EXPRESSING GENES IN A FUNGAL CELL
Ohmachi et al. Molecular organization of developmentally regulated Dictyostelium discoideum ubiquitin cDNAs
CN108840938A (en) A kind of fusion protein being made of pig albumin and Porcine interferon-gamma and preparation method thereof and a kind of Recombinant Swine long-acting interferon γ
CN1348003A (en) Hirudin gene hv 2-47k and its synthesis and expression
Clary et al. A cluster of six tRNA genes in Drosophila mitochondrial DNA that includes a gene for an unusual tRNAserAGY
CN108794638A (en) A kind of recombinant bovine long-acting interferon α and the fusion protein and preparation method thereof for preparing this long-acting interferon
Wildeman A putative ancestral actin gene present in a thermophilic eukaryote: novel combination of intron positions
CN101173003A (en) Agkistrodon venom prothrombin activator, its coding sequence and use
CN101134963A (en) Cascade expression method of recombinant human glandulae parathyroideae (1 to 34 peptide)
CN108840934B (en) Recombinant sheep long-acting interferon tau, fusion protein for preparing long-acting interferon tau and preparation method of fusion protein
AU2002345249A1 (en) Identification and cloning of the receptor gene for symbiotic nitrogen fixation
CN108840935A (en) A kind of fusion protein being made of sheep albumin and sheep interferon gamma and preparation method thereof and a kind of recombination sheep long-acting interferon γ
CN116083401B (en) Cas enzymes and systems and uses
CN108794637A (en) A kind of canine recombinant long-acting interferon α and the fusion protein and preparation method thereof for preparing this long-acting interferon
Prasad et al. A Plasmodium yoelii yoelii erythrocyte binding protein that uses Duffy binding-like domain for invasion: a rodent model for studying erythrocyte invasion
CN107365390A (en) A kind of fusion protein being made up of pig albumin, Porcine interferon-gamma and pig interleukin 2 and 6 and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: TANG DEJIANG

Free format text: FORMER OWNER: MEI BOGAO

Effective date: 20050610

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20050610

Address after: 400020, building 8, building B, hung Cheng Building, Jianxin East Road, Jiangbei District, Chongqing

Applicant after: Tang Dejiang

Address before: 400041, 5 floor, biochemical garden, four street, 70 garden, Chongqing hi tech Zone

Applicant before: Mei Bogao

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication